Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis.

By R. Pasqualini, E. Koivunen, R. Kain, J. Lahdenranta, M. Sakamoto, A. Stryhn, R. Ashmun, L. Shapiro, W. Arap, Erkki Ruoslahti. Cancer Research, 2000

885 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/18d600398aed00132eec9ce9684162edfc104e12

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Citations in the corpus

Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. (2014, background): “Colombo G, Curnis F, De Mori GMS, Gasparri A, Longoni C, Sacchi A, Longhi R, Corti A. Structure-Activity Relationships of Linear and Cyclic Peptides Containing the NGR Tumorhoming Motif.”
To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. (2010, background): “NGR (Asn–Gly–Arg) peptide is reported to bind to the aminopeptidase [60].”
Phage display technology: applications and innovations (2005, unknown): “Aminopeptidase N CNGRCVSGCAGRC Pasqualini et al. (2000)”
An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites (2019, background): “Thus, we discuss the relationship between targeting mechanisms and physicochemical factors of nanocarriers as well as pathophysiological characteristics of the tumour microenvironment (TME).”
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come (2016, background): “the ability to bind to aminopeptidase (Pasqualini et al., 2000), and this represents a strategy for targeting MMPs.”